TY - JOUR
T1 - -Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure
AU - Di Campli, Cristiana
AU - Santoro, Michele Cosimo
AU - Gaspari, Rita
AU - Merra, Giuseppe
AU - Zileri Dal Verme, Lorenzo
AU - Zocco, Maria Assunta
AU - Piscaglia, Anna Chiara
AU - Di Gioacchino, Giorgia
AU - Novi, Maria Luisa
AU - Santoliquido, Angelo
AU - Flore, Roberto Antonio
AU - Tondi, Paolo
AU - Proietti, Rodolfo
AU - Gasbarrini, Giovanni Battista
AU - Pola, Paolo
AU - Gasbarrini, Antonio
PY - 2005
Y1 - 2005
N2 - Abstract
BACKGROUND AND AIM: Molecular adsorbent recycling system (MARS) treatment is able to remove both hydrosoluble and small- and medium-sized lipophilic toxins. MARS plays an important role in modifying liver failure complications, such as hepatorenal syndrome and hepatic encephalopathy. We sought to evaluate the clinical efficacy and safety of a MARS device in a consecutive series of hepatic failure patients.
MATERIALS: Twenty patients with acute liver failure, transplantation failure, or acute on chronic liver failure fulfilled the inclusion criteria of total bilirubin > or =10 mg/dL and at least one of the following: hepatic encephalopathy (HE) > or =II grade, hepatorenal syndrome (HRS) for chronic patients or total bilirubin > or =5 mg/dL and HE > or =I grade for acute patients.
RESULTS: MARS was able to reduce cholestatic parameters and improve neurologic status and renal function parameters in all treated patients. We also observed an improvement in the 3-month survival rate compared to the expected outcome in patients with MELD scores between 20 and 29, as well as 30 and 39.
CONCLUSIONS: Based on these results, we confirm the safety and clinical efficacy of MARS treatment, with the best results in patients with MELD score of 20 to 29. Further studies are necessary to confirm whether this treatment is able to modify patient outcomes and prognosis.
AB - Abstract
BACKGROUND AND AIM: Molecular adsorbent recycling system (MARS) treatment is able to remove both hydrosoluble and small- and medium-sized lipophilic toxins. MARS plays an important role in modifying liver failure complications, such as hepatorenal syndrome and hepatic encephalopathy. We sought to evaluate the clinical efficacy and safety of a MARS device in a consecutive series of hepatic failure patients.
MATERIALS: Twenty patients with acute liver failure, transplantation failure, or acute on chronic liver failure fulfilled the inclusion criteria of total bilirubin > or =10 mg/dL and at least one of the following: hepatic encephalopathy (HE) > or =II grade, hepatorenal syndrome (HRS) for chronic patients or total bilirubin > or =5 mg/dL and HE > or =I grade for acute patients.
RESULTS: MARS was able to reduce cholestatic parameters and improve neurologic status and renal function parameters in all treated patients. We also observed an improvement in the 3-month survival rate compared to the expected outcome in patients with MELD scores between 20 and 29, as well as 30 and 39.
CONCLUSIONS: Based on these results, we confirm the safety and clinical efficacy of MARS treatment, with the best results in patients with MELD score of 20 to 29. Further studies are necessary to confirm whether this treatment is able to modify patient outcomes and prognosis.
KW - Catholic university experience
KW - Catholic university experience
UR - http://hdl.handle.net/10807/21198
M3 - Article
SP - 2547
EP - 2550
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
ER -